標(biāo)題: Titlebook: Biology and Treatment of Leukemia and Bone Marrow Neoplasms; Vinod Pullarkat,Guido Marcucci Book 2021 Springer Nature Switzerland AG 2021 [打印本頁] 作者: cucumber 時(shí)間: 2025-3-21 17:28
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms影響因子(影響力)
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms影響因子(影響力)學(xué)科排名
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms網(wǎng)絡(luò)公開度
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms被引頻次
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms被引頻次學(xué)科排名
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms年度引用
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms年度引用學(xué)科排名
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms讀者反饋
書目名稱Biology and Treatment of Leukemia and Bone Marrow Neoplasms讀者反饋學(xué)科排名
作者: 猛擊 時(shí)間: 2025-3-21 22:24 作者: 紅潤 時(shí)間: 2025-3-22 03:31 作者: enchant 時(shí)間: 2025-3-22 05:17
https://doi.org/10.1007/978-3-658-17357-9-AHN. The clinical presentation of SM can range from indolent to advanced depending on extent of mast cell burden and genetic profile. In the case of indolent SM, the goal of treatment is to control mediator release-related effects?as well as to reduce mast cell burden. In the case of SM-AHN, therap作者: 加花粗鄙人 時(shí)間: 2025-3-22 12:03 作者: 搖曳的微光 時(shí)間: 2025-3-22 15:35
Systemic Mastocytosis: Advances in Diagnosis and Current Management,-AHN. The clinical presentation of SM can range from indolent to advanced depending on extent of mast cell burden and genetic profile. In the case of indolent SM, the goal of treatment is to control mediator release-related effects?as well as to reduce mast cell burden. In the case of SM-AHN, therap作者: Fillet,Filet 時(shí)間: 2025-3-22 18:13
0927-3042 ment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students..978-3-030-78313-6978-3-030-78311-2Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: 失敗主義者 時(shí)間: 2025-3-22 21:11
0927-3042 targets for leukemia therapy.Provides comprehensive coverage.This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatment作者: 語源學(xué) 時(shí)間: 2025-3-23 01:45
https://doi.org/10.1007/978-3-662-53687-2ologic neoplasms have moved from traditional histology and immunophenotyping to integration of cytogenetic and genomic alterations. Using illustrative cases, this chapter provides an overview of the utility of using genomic data for prognostication as well as treatment decision-making for patients with bone marrow neoplasms.作者: Insatiable 時(shí)間: 2025-3-23 08:45 作者: BRINK 時(shí)間: 2025-3-23 09:53 作者: ARENA 時(shí)間: 2025-3-23 14:58 作者: 分開如此和諧 時(shí)間: 2025-3-23 21:03 作者: Tractable 時(shí)間: 2025-3-24 02:05
Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices,ery year although the incidence appears increased in patients originating from Latin America (Douer in Best Pract Res Clin Haematol 16:357–367, 2003). Notably, the median age at diagnosis is approximately 40?years which is significantly lower than in AML where the median age is 68?years.作者: 厭倦嗎你 時(shí)間: 2025-3-24 05:40 作者: 無法解釋 時(shí)間: 2025-3-24 08:04 作者: 安心地散步 時(shí)間: 2025-3-24 14:11 作者: Lasting 時(shí)間: 2025-3-24 17:17 作者: machination 時(shí)間: 2025-3-24 20:41
Die wichtigsten Kommunikationsmodelleluding those with . deletions/mutations who previously had a dismal outcome with conventional chemoimmunotherapy. Allogeneic HCT is a potentially curative option for selected younger patients with?multiply relapsed high-risk disease.作者: Watemelon 時(shí)間: 2025-3-25 02:42
Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma,hniques to detect this entity are complex and are not widely available. This chapter discusses various subsets of ALL and describes our approach to the accurate classification and prognostication of these cases.作者: 救護(hù)車 時(shí)間: 2025-3-25 07:07
Current and Emerging Therapies for Acute Myeloid Leukemia,topoietic cell transplantation with curative intent. Progress is also being made in the field of monoclonal antibodies targeting leukemia antigens and other immunotherapies and many such agents are currently under active investigation.作者: Expressly 時(shí)間: 2025-3-25 08:34
Chronic Lymphocytic Leukemia (CLL): Biology and Therapy,luding those with . deletions/mutations who previously had a dismal outcome with conventional chemoimmunotherapy. Allogeneic HCT is a potentially curative option for selected younger patients with?multiply relapsed high-risk disease.作者: sphincter 時(shí)間: 2025-3-25 14:55 作者: 沐浴 時(shí)間: 2025-3-25 18:59
Die wichtigsten Kommunikationsmodellehypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.作者: 滔滔不絕的人 時(shí)間: 2025-3-25 21:10
Advances in Diagnosis and Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndrom using the latest next generation sequencing technology can sequence an entire human genome within a few hours. Diagnosis and prognostication of hematologic neoplasms have moved from traditional histology and immunophenotyping to integration of cytogenetic and genomic alterations. Using illustrative作者: 尾巴 時(shí)間: 2025-3-26 03:06
Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma,decade with advances in sequencing and other molecular techniques. Besides recurrent chromosomal abnormalities detected by karyotyping or fluorescence in situ hybridization, these leukemias/lymphomas are characterized by a variety of mutations, gene rearrangements as well as copy number alterations.作者: 預(yù)兆好 時(shí)間: 2025-3-26 04:21 作者: creditor 時(shí)間: 2025-3-26 11:40 作者: 注入 時(shí)間: 2025-3-26 14:19
Current Management and New Developments in the Treatment of ALL, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.作者: Heresy 時(shí)間: 2025-3-26 17:51
CML Chapter,myeloid leukemia (CML) [Hochhaus et al. in N Engl J Med 376:917–927, 2017]. The treatment of patients with CML has changed dramatically since the approval of imatinib and other TKIs. Before the TKI era, newly diagnosed patients would undergo HLA typing to try to identify a well-matched donor, and th作者: Emg827 時(shí)間: 2025-3-26 23:07
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome,nia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to 作者: 拖網(wǎng) 時(shí)間: 2025-3-27 03:39
Chronic Lymphocytic Leukemia (CLL): Biology and Therapy, the bone marrow and lymphoid organs. Signaling via the B-cell receptor and Bruton tyrosine kinase (BTK) as well as resistance to apoptosis mediated by Bcl-2 are hallmarks of CLL biology and have been exploited in recent years to revolutionize management. As a result of the development of novel ther作者: 嚙齒動(dòng)物 時(shí)間: 2025-3-27 05:35
Systemic Mastocytosis: Advances in Diagnosis and Current Management,solated skin involvement is termed cutaneous mastocytosis (CM) and the term systemic mastocytosis (SM) refers to multi-organ involvement, most commonly of the bone marrow, skin, liver, and spleen. A subset of patients with SM have an associated clonal hematologic neoplasm which is most commonly myel作者: botany 時(shí)間: 2025-3-27 13:10 作者: 向下 時(shí)間: 2025-3-27 15:13
Current Management and New Developments in the Treatment of ALL, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.作者: Neutral-Spine 時(shí)間: 2025-3-27 17:58 作者: conspicuous 時(shí)間: 2025-3-27 21:58
https://doi.org/10.1007/978-3-662-59220-5decade with advances in sequencing and other molecular techniques. Besides recurrent chromosomal abnormalities detected by karyotyping or fluorescence in situ hybridization, these leukemias/lymphomas are characterized by a variety of mutations, gene rearrangements as well as copy number alterations.作者: corporate 時(shí)間: 2025-3-28 04:08 作者: mitten 時(shí)間: 2025-3-28 09:25
Die wichtigsten Kommunikationsmodelle slow progress, the last 5?years have witnessed remarkable progress in AML therapy with the approval of multiple highly active and well-tolerated novel therapies. Notable among these are agents targeting driver mutations including FLT3, IDH1/2 as well as the Bcl-2 inhibitor venetoclax. The combinati作者: 纖細(xì) 時(shí)間: 2025-3-28 13:42 作者: 時(shí)間等 時(shí)間: 2025-3-28 16:44 作者: freight 時(shí)間: 2025-3-28 19:19
Die wichtigsten Kommunikationsmodellenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to 作者: 發(fā)電機(jī) 時(shí)間: 2025-3-29 00:56
Die wichtigsten Kommunikationsmodelle the bone marrow and lymphoid organs. Signaling via the B-cell receptor and Bruton tyrosine kinase (BTK) as well as resistance to apoptosis mediated by Bcl-2 are hallmarks of CLL biology and have been exploited in recent years to revolutionize management. As a result of the development of novel ther作者: Neolithic 時(shí)間: 2025-3-29 05:05 作者: 樹木中 時(shí)間: 2025-3-29 10:08 作者: 課程 時(shí)間: 2025-3-29 13:34 作者: Mundane 時(shí)間: 2025-3-29 17:06
Cancer Treatment and Researchhttp://image.papertrans.cn/b/image/187667.jpg
